3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
162
Carcinoma, Non-Small-Cell Lung
109
Lung Neoplasms
54
Hodgkin Disease
22
Neoplasm Metastasis
16
Recurrence
15
Lymphoma
15
Neoplasms
14
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
10
Adenocarcinoma of Lung
10
Sarcoma
9
Rhabdomyosarcoma
9
Uterine Cervical Neoplasms
8
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
6
Ovarian Neoplasms
5
Mesothelioma, Malignant
5
Breast Neoplasms, Male
5
Small Cell Lung Carcinoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
NSCLC
4
Multiple Myeloma
4
Brain Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Mesothelioma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Interventions
Carboplatin
15
Pemetrexed
7
Paclitaxel
7
pembrolizumab
4
durvalumab
4
osimertinib
3
entinostat
3
Gemcitabine
3
Erlotinib Hydrochloride
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
efatutazone
2
atezolizumab
2
Radiosurgery
2
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
napabucasin
1
ficlatuzumab
1
exemestane
1
cobimetinib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
alectinib
1
aflutinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Respiratory Tract Neoplasms
×
Vinorelbine
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled